Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07456033 · ClinicalTrials.gov registry record · Phase 3
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
A Phase 3 study, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 456
- Enrollment target
NCT07456033 is a Phase 3 study that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 456 participants.
The verdict
NCT07456033, a Phase 3 study, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 456 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).
Interventions
- DRUG Placebo
- DRUG Depemokimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2026-03-13 |
| Est. Completion | 2030-07-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07456033
The ClinicalTrials.gov registry entry for NCT07456033 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 456 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07456033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07456033 about?
NCT07456033 is a clinical study titled "A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma". The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).
What is the current status of trial NCT07456033?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 456 participants. The study started on 2026-03-13. Estimated completion is 2030-07-08.
What interventions are being tested in trial NCT07456033?
The interventions under investigation include: Placebo (DRUG), Depemokimab (DRUG).
Who is sponsoring clinical trial NCT07456033?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.